FDA
-
-
-
-
-
-
-
CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
-
-
-
-
-
-
-
CohBar to Host Key Opinion Leader Meeting on Antifibrotic Peptides for the Potential Treatment of Idiopathic Pulmonary Fibrosis
-
-
-
-
-
-
-
CohBar to Resume its Phase 1a/1b Clinical Trial
-
-
-
-
-
-
-
CohBar, Inc.’s CEO Simon Allen to Present at the 1st Annual H.C. Wainwright & Co. NASH Investor Conference in New York
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

